Moyamoya Syndrome Presenting as Migraine-Like Headache: MRI, MRA, DSA Imaging Clues and the Clinical Significance of Cerebrovascular Reserve
Subtitle
A radiologist’s approach to a 47-year-old man with recurrent headache, photophobia, phonophobia, and nausea, with emphasis on abnormal collateral vessels, severe proximal M1 stenosis, multimodal neurovascular imaging, differential diagnosis, revascularization, and the emerging role of AI.
Executive Clinical Summary
A 47-year-old man presented with recurrent headaches accompanied by photophobia, phonophobia, and nausea. Each episode lasted approximately 2–3 hours and occurred about four times per month. Neurologic examination did not reveal a definite abnormality.
Clinically, the presentation could easily be interpreted as migraine. The imaging findings, however, changed the diagnostic perspective.
Brain MRI demonstrated multiple abnormal vascular flow-void structures along the left Sylvian fissure. TOF-MRA demonstrated severe stenosis of the proximal left M1 segment with reduced visualization of the distal MCA branches. The combination of major intracranial arterial stenosis and an abnormal collateral vascular network strongly suggests moyamoya vasculopathy.
The case is presented as moyamoya syndrome (MMS). Importantly, the distinction between moyamoya disease (MMD) and moyamoya syndrome cannot be established from vascular imaging alone. MMS implies an associated underlying condition, and the available clinical information does not specify that underlying etiology. Therefore, the imaging diagnosis is best understood as moyamoya vasculopathy, while the etiologic classification requires clinical and laboratory assessment.
The most important radiologic lesson is simple:
Do not stop at “MCA stenosis.” Look for the vascular network that the brain has developed in response to chronic arterial insufficiency.
Key Clinical Questions
- Can moyamoya vasculopathy present primarily with migraine-like headache?
- What does severe M1 stenosis mean when abnormal collateral vessels are also present?
- Which MRI and MRA findings should alert the radiologist?
- When is DSA necessary?
- Why is cerebrovascular reserve more important than stenosis severity alone?
- How can AI assist without replacing expert neurovascular interpretation?
Introduction
Headache is one of the most familiar symptoms in clinical medicine. Migraine, tension-type headache, medication-overuse headache, and primary headache disorders account for a large proportion of recurrent headaches.
The diagnostic challenge arises when a headache phenotype looks familiar but the underlying biology is not.
Moyamoya angiopathy is a chronic cerebrovascular disorder characterized by progressive stenosis or occlusion of intracranial arteries and development of fragile collateral vessels. Headache can mimic migraine, and contemporary reviews emphasize that migraine-like headache is a recognized clinical manifestation of moyamoya angiopathy.
That is precisely why imaging matters.
In the present case, the symptoms initially suggested migraine. Yet MRI demonstrated abnormal vascular structures around the left Sylvian fissure, while TOF-MRA showed severe proximal left M1 stenosis and decreased distal MCA visualization. These findings transformed the clinical question from “What type of headache is this?” to “Why is the cerebral circulation developing this collateral pattern?”
That change in question is the essence of neuroradiologic reasoning.
Clinical Hook
A patient can have photophobia, phonophobia, nausea, and recurrent headache and still have a significant cerebrovascular disorder.
The headache phenotype itself does not establish the vascular diagnosis.
A 2025 consensus review notes that headache is common in moyamoya angiopathy and may resemble migraine or tension-type headache. The mechanisms may involve impaired cerebrovascular autoregulation, microvascular ischemia, and collateral-vessel development.
Therefore, the imaging context becomes particularly important when headache is new, changing, refractory, accompanied by transient neurologic symptoms, or associated with abnormal neurovascular imaging.
In this case, the decisive clue was not the headache.
It was the combination of:
proximal M1 stenosis + reduced distal MCA branches + abnormal collateral vessels.
Learning Objectives
By the end of this article, readers should be able to:
- Recognize the characteristic imaging pattern of moyamoya vasculopathy.
- Distinguish a simple intracranial arterial stenosis from a stenosis associated with moyamoya-type collateralization.
- Understand the complementary roles of MRI, TOF-MRA, CTA, perfusion imaging, and DSA.
- Recognize the importance of cerebrovascular reserve in treatment planning.
- Understand the distinction between moyamoya disease and moyamoya syndrome.
- Evaluate realistic opportunities and limitations for AI-assisted moyamoya imaging.
Case Presentation
Patient Profile
Age: 47 years
Sex: Male
Symptoms
The patient experienced recurrent headaches accompanied by:
- Photophobia
- Phonophobia
- Nausea
Each episode lasted approximately 2–3 hours and occurred approximately four times per month. Photophobia frequently triggered the headache episodes. Neurologic examination did not demonstrate a definite abnormality.
Initial Clinical Impression
The symptom complex was compatible with a migraine-like headache phenotype.
However, the imaging evaluation revealed an unexpected neurovascular abnormality.
MRI
MRI demonstrated multiple abnormal vascular structures along the left Sylvian fissure.
TOF-MRA
TOF-MRA demonstrated:
- Severe stenosis of the proximal left M1 segment.
- Reduced visualization of distal MCA branches.
- Abnormal collateral vascular development.
The coexistence of these findings substantially increases suspicion for moyamoya vasculopathy.
Final Diagnosis Presented in the Case
Moyamoya syndrome (MMS).
However, the underlying associated systemic or acquired condition is not reported in the available clinical information. Therefore, the radiologic finding establishes a moyamoya-pattern vasculopathy, while classification as MMS requires appropriate etiologic evaluation.
Anatomy Review
The relevant vascular anatomy includes the terminal internal carotid arteries and their major intracranial branches, particularly the anterior cerebral artery and middle cerebral artery.
The MCA is especially relevant in this case because the principal vascular abnormality involves the proximal left M1 segment.
When a major intracranial artery becomes progressively stenotic, cerebral perfusion may become dependent on secondary pathways. These may include:
- Lenticulostriate perforators
- Leptomeningeal collaterals
- Transdural collateral pathways
- Other basal collateral networks
The abnormal vascular structures may become conspicuous on MRI as flow voids or enhancing small vessels.
Understanding the anatomy is therefore essential because the diagnostic clue is not simply arterial narrowing. It is the relationship between stenosis and compensatory collateralization.
Pathophysiology
The fundamental process is:
Progressive arterial stenosis or occlusion → reduced cerebral perfusion → compensatory collateral development → fragile collateral network → ischemic and/or hemorrhagic risk.
The brain has limited tolerance for prolonged reductions in oxygen and glucose delivery. When major arteries progressively narrow, compensatory mechanisms recruit alternative vascular pathways.
One characteristic consequence is the development of numerous small collateral vessels at the brain base.
On angiography, these vessels may produce the classic “puff of smoke” appearance.
The paradox is clinically important.
The collateral vessels are protective because they preserve cerebral perfusion, but some collateral channels are fragile and may contribute to hemorrhagic risk.
Thus, moyamoya should not be conceptualized simply as “arterial stenosis.”
It is better understood as a dynamic cerebrovascular adaptation to progressive arterial insufficiency.
Why the Migraine-Like Presentation Matters
The headache in moyamoya can resemble migraine.
That creates a potential diagnostic trap.
Photophobia, phonophobia, nausea, and recurrent headache do not exclude an underlying vascular disorder. Recent literature emphasizes that headache associated with moyamoya can have a migraine phenotype and may improve after successful revascularization in some patients, although headache outcomes are heterogeneous.
The practical lesson is not that every migraine patient requires extensive vascular imaging.
Rather, clinicians should reconsider the diagnosis when the headache is:
- New or substantially changed.
- Refractory or atypical.
- Associated with transient neurologic symptoms.
- Triggered or worsened by physiologic stress.
- Accompanied by abnormal MRI or MRA findings.
The distinction is clinically meaningful because treating a patient as having uncomplicated migraine does not address the underlying cerebral hemodynamic problem.
Imaging Features
Table 1. Imaging Modalities in Moyamoya Vasculopathy
| Modality | Major Strength | Important Finding | Clinical Role |
|---|---|---|---|
| Noncontrast CT | Rapid assessment | Hemorrhage, chronic infarction | Acute presentation |
| CTA | Vascular anatomy | Stenosis, occlusion, collaterals | Rapid vascular assessment |
| MRI | Brain parenchyma | Infarction, gliosis, atrophy | Structural assessment |
| TOF-MRA | Noninvasive angiography | Intracranial stenosis and distal branch reduction | Screening/follow-up |
| Contrast-enhanced MRI | Collateral visualization | Abnormal enhancing vessels | Collateral assessment |
| DSA | Highest spatial/temporal resolution | Detailed collateral architecture | Confirmation and surgical planning |
| Perfusion MRI/CT | Hemodynamics | Regional perfusion deficit | Hemodynamic assessment |
| SPECT/PET | Cerebral perfusion/reserve | Regional blood flow and reserve | Functional assessment |
The available case material specifically emphasizes MRI/MRA, DSA, and perfusion imaging as complementary components of a multimodal strategy.
A 2026 scoping review similarly concluded that DSA remains central for confirmation and surgical planning, while MRI-based structural, vascular, and hemodynamic techniques provide important complementary information.
Source Figure 1 — MRI and TOF-MRA
Figure 1. Brain MRI and TOF-MRA demonstrating abnormal collateral vessels and left M1 stenosis.
Figure Legend:
(A) Axial T2-weighted imaging demonstrates multiple abnormal vascular flow-void structures around the left Sylvian fissure.
(B) Contrast-enhanced T1-weighted imaging demonstrates multiple small enhancing vessels in the same region.
(C) TOF-MRA demonstrates severe stenosis of the proximal left M1 segment with reduced visualization of distal MCA branches.
Radiologist Interpretation
The findings are not adequately explained by an isolated focal MCA stenosis. The associated abnormal collateral vascular structures provide an important clue toward moyamoya-pattern vasculopathy.
Clinical Significance
The key imaging combination is:
stenosis + distal branch reduction + collateralization.
This combination should prompt consideration of moyamoya vasculopathy and assessment of the broader intracranial circulation.
ALT Text
“Brain MRI and TOF-MRA demonstrating abnormal left Sylvian fissure collateral vessels and severe proximal left M1 stenosis.”
Source Figure 2 — MRA Vascular Abnormality
Figure 2. MRA demonstrating severe proximal left M1 stenosis and abnormal collateral vessels.
The case describes severe proximal left M1 stenosis accompanied by an abnormal collateral vascular network.
Radiologist Interpretation
The proximal left M1 segment demonstrates severe stenotic narrowing. Abnormal collateral vessels are present around the affected circulation.
Clinical Significance
The critical observation is not simply the severity of M1 stenosis. The presence and configuration of compensatory vessels suggest a chronic hemodynamic process rather than an isolated focal stenotic lesion.
ALT Text
“MRA demonstrating severe proximal left M1 stenosis with abnormal collateral vascular network.”
“Puff of Smoke” Sign
The classic angiographic appearance of moyamoya is the puff of smoke sign.
The term describes a network of small collateral vessels that develops around the basal cerebral circulation.
However, the sign should not be interpreted in isolation.
A radiologist should systematically evaluate:
- Which arteries are stenotic?
- Is the process unilateral or bilateral?
- Is the terminal ICA involved?
- Are the proximal ACA and MCA segments involved?
- How extensive are the collateral vessels?
- Are basal ganglia perforators enlarged?
- Is there evidence of ischemic injury?
- Are microbleeds or hemorrhage present?
- Is there evidence of impaired cerebral perfusion or reserve?
This comprehensive approach is more reliable than simply identifying the phrase “puff of smoke.”
Ivy Sign
The ivy sign refers to linear or gyriform high signal along the cortical surface, particularly on FLAIR or contrast-enhanced T1-weighted imaging.
It can reflect prominent leptomeningeal collateral circulation and altered cortical vascular dynamics.
The finding is not pathognomonic.
Its value increases when interpreted together with arterial stenosis, collateralization, and the overall clinical context.
Brush Sign
The brush sign is associated with increased visibility of deep medullary veins on susceptibility-sensitive imaging.
It has been investigated as a marker of hemodynamic stress or severity.
However, it should not be used as a standalone diagnostic sign.
The case material appropriately emphasizes that brush sign may function as a supportive imaging biomarker rather than a definitive diagnostic criterion.
CT and CTA
CT may be normal or relatively nonspecific in patients with moyamoya vasculopathy.
Nevertheless, it remains valuable, particularly in acute presentations.
CT can demonstrate:
- Acute intracranial hemorrhage
- Chronic infarction
- Watershed injury
- Cerebral atrophy
- Basal ganglia hemorrhage
- Chronic ischemic changes
CTA can provide information regarding:
- Terminal ICA stenosis
- MCA/ACA stenosis
- Occlusion
- Collateral vessels
- Abnormal vascular networks
A normal or near-normal CT should therefore not be interpreted as excluding moyamoya.
DSA: Why It Still Matters
Digital subtraction angiography remains particularly important because it provides high-resolution visualization of vascular architecture and collateral pathways.
The 2026 imaging scoping review identifies DSA as the diagnostic reference standard, particularly for disease confirmation and surgical planning.
DSA can answer questions that routine MRA may not fully resolve:
- Which arterial segments are involved?
- What is the exact collateral pattern?
- How extensive are transdural collaterals?
- What is the relationship between external and internal carotid systems?
- Which territories remain dependent on vulnerable collateral pathways?
- What vascular anatomy should guide revascularization planning?
Thus, MRI/MRA and DSA should not be considered competing tests.
They are complementary.
Cerebrovascular Reserve: The Question That Changes Management
One of the most important concepts in moyamoya is cerebrovascular reserve (CVR).
A severe stenosis does not automatically mean that the affected brain tissue is critically hypoperfused.
Conversely, a patient with relatively modest-appearing stenosis may have substantial hemodynamic compromise.
Therefore, the clinically meaningful question is:
Can the cerebral circulation increase blood flow when metabolic demand rises?
Perfusion assessment may involve:
- SPECT
- PET
- CT perfusion
- Dynamic susceptibility contrast MRI
- Arterial spin labeling
- Other cerebrovascular reserve techniques
The case material emphasizes that treatment decisions should consider not only arterial narrowing but also cerebral blood flow and cerebrovascular reserve.
Table 2. Structural Versus Hemodynamic Assessment
| Question | Structural Imaging | Hemodynamic Imaging |
|---|---|---|
| Is an artery stenotic? | Yes | Indirect |
| Are collaterals present? | Yes | Indirect |
| Is there infarction? | Yes | May demonstrate consequence |
| Is perfusion reduced? | Limited | Yes |
| Is CVR impaired? | No/limited | Yes |
| Is surgery being considered? | Important | Often critical |
| Can anatomy and physiology be integrated? | Partially | Yes |
Differential Diagnosis
Table 3. Differential Diagnosis of Moyamoya-Pattern Intracranial Stenosis
| Diagnosis | Key Imaging Finding | Clinical Clue | Differentiating Point |
|---|---|---|---|
| Moyamoya disease | Progressive steno-occlusion + characteristic collaterals | Isolated moyamoya phenotype | No qualifying associated disorder |
| Moyamoya syndrome | Moyamoya-pattern vasculopathy | Associated disease/condition | Etiology must be established clinically |
| Intracranial atherosclerosis | Focal or multifocal stenosis | Vascular risk factors | Collateral pattern differs |
| CNS vasculitis | Multifocal stenosis | Inflammatory/systemic context | Vessel-wall and clinical findings |
| Arterial dissection | Focal stenosis/occlusion | Acute or subacute symptoms | Vessel-wall abnormality |
| AVM | Nidus and arteriovenous shunting | Hemorrhage/seizure | Distinct vascular architecture |
| Other secondary arteriopathies | Variable stenosis | Relevant systemic history | Etiologic context |
The case specifically emphasizes atherosclerotic MCA stenosis, vasculitis, AVM, radiation-associated vasculopathy, neurofibromatosis, systemic lupus erythematosus, antiphospholipid syndrome, meningitis, sickle-cell disease, and other conditions as considerations when evaluating moyamoya-pattern vascular disease.
Moyamoya Disease Versus Moyamoya Syndrome
This distinction deserves special attention.
Moyamoya disease generally refers to the characteristic progressive occlusive arteriopathy without an explanatory associated disorder.
Moyamoya syndrome refers to a similar angiographic phenotype occurring in association with another condition.
Possible associated conditions include autoimmune disease, prior cranial irradiation, neurofibromatosis type 1, sickle-cell disease, Down syndrome, and other systemic or acquired disorders.
The important point is that vascular imaging cannot independently establish the underlying etiology.
In this case, the final diagnosis is presented as MMS, but the associated condition is not provided. Therefore, the appropriate radiologic wording would be:
“Findings are consistent with moyamoya-pattern vasculopathy. Clinical evaluation for an associated condition is required to distinguish moyamoya disease from moyamoya syndrome.”
This wording prevents overinterpretation.
Multimodal Imaging Strategy
Table 4. Multimodal Imaging Comparison
| Modality | Strength | Limitation | Best Clinical Question |
|---|---|---|---|
| MRI | Parenchymal injury | Longer examination | Has brain injury occurred? |
| TOF-MRA | Noninvasive vascular assessment | Flow-related limitations | Where is stenosis? |
| CTA | Fast vascular imaging | Radiation/contrast | What is the vascular anatomy? |
| DSA | Detailed vascular architecture | Invasive | What is the exact collateral anatomy? |
| Perfusion MRI | Hemodynamic assessment | Protocol dependence | Is perfusion impaired? |
| SPECT | Cerebral perfusion/reserve | Radiation/tracer | How is regional reserve affected? |
| PET | Advanced metabolic assessment | Availability | What is regional cerebral physiology? |
| Vessel-wall MRI | Arterial wall characterization | Technical complexity | What is the nature of the arterial wall abnormality? |
High-Resolution Vessel-Wall MRI
Conventional MRA primarily evaluates the lumen.
High-resolution vessel-wall MRI asks a different question:
What is happening within the arterial wall?
Potentially useful parameters include:
- Wall thickening
- Enhancement
- Remodeling
- Outer vessel diameter
- Pattern of wall involvement
A 2025 systematic review and meta-analysis found that vessel-wall enhancement and remodeling characteristics are increasingly investigated in moyamoya and may help differentiate moyamoya from other intracranial vasculopathies, although standardization and additional validation remain necessary.
This is particularly relevant when the differential diagnosis includes:
- Atherosclerosis
- Vasculitis
- Dissection
- Moyamoya vasculopathy
The future of neurovascular imaging will likely move from a purely luminal question—
“How narrow is the artery?”
—to an integrated question:
“What is happening to the vessel wall, collateral circulation, cerebral perfusion, and brain tissue?”
Clinical Diagnostic Algorithm
The appropriate pathway depends on clinical context, imaging findings, institutional expertise, and the specific diagnostic question.
Treatment
Moyamoya is fundamentally different from an ordinary focal atherosclerotic stenosis.
The central therapeutic concept is revascularization.
The case describes aspirin initiation for stroke prevention and identifies direct or indirect revascularization as major treatment strategies.
Medical Therapy
Antiplatelet therapy may be used in selected patients, particularly in ischemic presentations.
However, medical treatment does not mechanically reverse the progressive arterial occlusive process.
Direct Revascularization
In adults, STA–MCA bypass is an important surgical strategy.
The superficial temporal artery is connected directly to a cortical MCA branch, creating an alternative route for cerebral blood flow.
Indirect Revascularization
Indirect procedures encourage development of new collateral vessels over time.
Examples include:
- Encephalomyosynangiosis
- Encephaloduroarteriosynangiosis
- Combined indirect procedures
The choice of surgical strategy depends on age, vascular anatomy, clinical phenotype, perfusion status, cerebrovascular reserve, and institutional expertise.
The 2021 Japanese guidelines emphasize revascularization as an important treatment strategy in appropriate patients with moyamoya disease.
When Should Treatment Be Considered?
Treatment decisions should not be based solely on headache frequency.
Relevant factors include:
- Recurrent TIA
- Prior ischemic stroke
- Hemodynamic impairment
- Reduced cerebrovascular reserve
- Progressive vascular disease
- Cerebral tissue injury
- Hemorrhagic risk
- Collateral architecture
- Overall clinical condition
The AHA/ASA scientific statement emphasizes the heterogeneity of adult moyamoya disease and syndrome and the need to integrate clinical, diagnostic, and therapeutic considerations rather than relying on a single imaging parameter.
Prognostic Imaging Follow-Up
Follow-up should evaluate more than the degree of stenosis.
Table 5. Follow-Up Imaging Checklist
| Domain | What to Evaluate |
|---|---|
| Arteries | Progression of stenosis |
| Contralateral circulation | New involvement |
| Collaterals | Development or regression |
| Bypass | Patency after surgery |
| Brain tissue | New infarction |
| Watershed regions | Chronic ischemic injury |
| White matter | Gliosis |
| Susceptibility imaging | Microbleeds |
| Hemorrhage | New intracranial bleeding |
| Perfusion | Regional cerebral blood flow |
| CVR | Functional reserve |
| Postoperative status | Perfusion improvement |
The case emphasizes that structural and hemodynamic information should be integrated during follow-up rather than repeatedly measuring stenosis alone.
Artificial Intelligence Perspective
AI Evidence: Promising, But Not Yet Autonomous
A 2024 systematic review and meta-analysis of deep-learning algorithms for MMD detection reported encouraging pooled diagnostic performance, but the evidence base consisted of only seven studies and remains vulnerable to dataset and external-validation limitations.
A 2026 review similarly describes AI applications in MMD as promising but still at an early stage of clinical validation.
This distinction is critical.
A model that recognizes an image pattern in a curated dataset is not equivalent to a clinically validated system operating across:
- Different MRI vendors
- Different field strengths
- Different acquisition protocols
- Pediatric and adult populations
- Different disease stages
- MMD and MMS
- Atherosclerosis
- Vasculitis
- Dissection
- Motion-degraded examinations
AI Workflow
Table 6. Proposed Clinical AI Workflow
| Stage | AI Function | Human Verification |
|---|---|---|
| DICOM ingestion | Protocol recognition | Radiographer/system validation |
| Image quality | Motion/artifact detection | Radiologist |
| MRA analysis | Stenosis detection | Radiologist |
| Collateral analysis | Vessel-pattern detection | Neuroradiologist |
| MRI analysis | Infarction/hemorrhage detection | Radiologist |
| Perfusion | Hemodynamic abnormality detection | Neurovascular team |
| Longitudinal comparison | Change detection | Radiologist |
| Report support | Structured findings | Radiologist approval |
| Risk stratification | Multimodal synthesis | Multidisciplinary team |
The AI should therefore function as a decision-support layer, not as an autonomous diagnostic authority.
AI Failure Modes
Table 7. Clinical AI Failure-Control Matrix
| Failure Mode | Potential Consequence | Required Human Check |
|---|---|---|
| False-negative stenosis | Missed vasculopathy | Review source MRA |
| False-positive stenosis | Unnecessary workup | Correlate with anatomy |
| Flow artifact | Incorrect narrowing | Review multiple sequences |
| Missed collateral network | Delayed diagnosis | Inspect Sylvian/basal regions |
| Poor image quality | Unreliable output | Repeat/alternative imaging |
| Domain shift | Performance degradation | Local validation |
| Unusual anatomy | Misclassification | Expert interpretation |
| MMD/MMS confusion | Incorrect etiologic labeling | Clinical assessment |
| Hallucinated report text | Wrong clinical conclusion | Human sign-off |
| Alert fatigue | Important findings ignored | Workflow optimization |
One of the most dangerous AI errors in this setting would not necessarily be failure to detect stenosis.
It could be failure to understand why the stenosis matters.
An algorithm might correctly identify M1 narrowing while failing to recognize that the accompanying collateral pattern fundamentally changes the differential diagnosis.
Enterprise Healthcare Workflow
A hospital-scale implementation could follow:
The AI orchestration layer should maintain:
- Model version
- Input examination
- Processing time
- Output
- Confidence/uncertainty
- Human modification
- Final radiologic interpretation
- Audit trail
This is especially important in a progressive cerebrovascular disease where longitudinal comparison may be clinically meaningful.
Enterprise AI Governance
Table 8. Hospital-Level Governance Framework
| Domain | Requirement |
|---|---|
| Validation | Local and external validation |
| Interoperability | DICOM/HL7/FHIR compatibility where applicable |
| Security | Protected clinical data |
| Auditability | Model and output logging |
| Monitoring | Performance surveillance |
| Drift detection | Protocol and population changes |
| Human oversight | Radiologist approval |
| Change management | Version-controlled deployment |
| Incident response | Defined escalation pathway |
| Vendor management | Performance and update monitoring |
The objective is not simply to install an AI algorithm.
The objective is to create a safe clinical system around the algorithm.
Healthcare Economics
Exact financial benefit cannot be responsibly calculated from the available case.
A qualitative ROI framework is therefore more appropriate:
ROI = (Financial Benefit − Total Cost of Ownership) / Total Cost of Ownership
Potential benefits may include:
- Earlier recognition of high-risk vascular disease
- More efficient neurovascular referrals
- Reduced diagnostic delay
- Structured longitudinal comparison
- Improved radiologist workflow
- More consistent imaging documentation
Potential costs include:
- AI licensing
- PACS/RIS integration
- Infrastructure
- Cybersecurity
- Validation
- Staff training
- Maintenance
- Governance
- Monitoring
No guaranteed financial return should be assumed.
Expert Insights
Expert Insight 1 — Radiologist Perspective
A focal MCA stenosis should never be interpreted in isolation when abnormal collateral vessels are present.
Expert Insight 2 — Headache Perspective
Migraine-like symptoms do not establish a primary headache disorder when neurovascular imaging is abnormal.
Expert Insight 3 — Neuroradiology Perspective
The combination of stenosis and collateralization is more diagnostically informative than stenosis severity alone.
Expert Insight 4 — MRI Perspective
Flow voids can become a subtle but important clue to abnormal vascular proliferation.
Expert Insight 5 — MRA Perspective
Reduced distal MCA visualization should be interpreted in relation to the proximal stenosis and collateral pathways.
Expert Insight 6 — Hemodynamic Perspective
Anatomical stenosis does not directly quantify tissue-level perfusion adequacy.
Expert Insight 7 — Neurosurgical Perspective
Surgical planning requires detailed understanding of vascular anatomy and hemodynamic compromise.
Expert Insight 8 — PACS Perspective
Longitudinal comparison should make vascular progression and postoperative bypass status readily visible.
Expert Insight 9 — AI Deployment Perspective
An AI model should identify suspicious vascular patterns but should not independently classify MMD versus MMS without clinical context.
Expert Insight 10 — Hospital CIO Perspective
The safety of clinical AI depends as much on governance, interoperability, auditability, and monitoring as on model accuracy.
Expert Insight 11 — Patient Journey Perspective
The major clinical value of recognizing moyamoya may be prevention of a future ischemic or hemorrhagic event rather than simply explaining today's headache.
Expert Insight 12 — Future Technology Perspective
The most valuable future systems will integrate vascular anatomy, vessel-wall characteristics, cerebral perfusion, parenchymal injury, and longitudinal change rather than analyzing a single image sequence.
Clinical Pearls
- Migraine-like headache can occur in moyamoya angiopathy.
- Normal neurologic examination does not exclude clinically relevant cerebrovascular disease.
- M1 stenosis alone has a broad differential diagnosis.
- M1 stenosis plus abnormal collateral vessels should raise suspicion for moyamoya.
- Sylvian fissure flow voids can be an important clue.
- TOF-MRA is useful for noninvasive intracranial vascular assessment.
- DSA remains important for detailed vascular characterization and surgical planning.
- “Puff of smoke” describes collateral architecture rather than disease etiology.
- Ivy sign should be interpreted in the broader vascular context.
- Brush sign is supportive rather than pathognomonic.
- Cerebrovascular reserve may be more clinically informative than stenosis severity alone.
- MMD and MMS require conceptual distinction.
- Imaging cannot independently establish the associated systemic cause of MMS.
- Adult treatment frequently focuses on revascularization when clinically appropriate.
- AI should support, not replace, expert neurovascular interpretation.
Common Diagnostic Pitfalls
Pitfall 1 — Calling the lesion “atherosclerotic MCA stenosis” too early
The collateral pattern may provide a more important diagnostic clue than the stenosis itself.
Pitfall 2 — Assuming migraine excludes vascular disease
Headache phenotype is not a substitute for appropriate clinical and imaging assessment.
Pitfall 3 — Ignoring the Sylvian fissure
Abnormal clusters of vessels or flow voids may be subtle.
Pitfall 4 — Looking only at the proximal artery
The distal branch pattern and collateral network must also be evaluated.
Pitfall 5 — Equating stenosis severity with hemodynamic severity
Perfusion and CVR may provide additional information.
Pitfall 6 — Diagnosing MMS from imaging alone
The associated condition must be established clinically.
Pitfall 7 — Treating an AI result as a diagnosis
The radiologist remains responsible for integrating imaging and clinical information.
FAQ
What is moyamoya syndrome?
Moyamoya syndrome is a moyamoya-pattern cerebrovascular arteriopathy occurring in association with another underlying condition. The imaging phenotype may resemble moyamoya disease, but the etiologic distinction requires clinical assessment.
What is the key MRI finding?
Abnormal vascular flow voids or enhancing collateral vessels, particularly when associated with major intracranial arterial stenosis, should raise suspicion.
What is the key MRA finding?
Severe stenosis or occlusion of major intracranial arteries accompanied by abnormal collateralization and reduced distal arterial visualization.
What is the “puff of smoke” sign?
It describes the angiographic appearance of numerous small collateral vessels developing around the basal cerebral circulation.
Is DSA still necessary?
DSA remains highly important for detailed vascular characterization and surgical planning, although noninvasive imaging provides substantial complementary information.
Can moyamoya cause migraine-like headache?
Yes. Headache in moyamoya angiopathy can resemble migraine, although headache phenotype alone is not diagnostic.
Is MRI/MRA enough to assess cerebral perfusion?
Not necessarily. Additional perfusion or cerebrovascular-reserve assessment may be required when treatment decisions depend on hemodynamic status.
What is the role of vessel-wall MRI?
It may provide additional information about arterial-wall characteristics and may assist differential diagnosis, but its clinical role continues to evolve.
Can AI diagnose moyamoya?
AI can potentially assist detection and classification, but current evidence does not justify replacing expert interpretation or multidisciplinary clinical assessment.
Is surgery always required?
No. Management depends on clinical presentation, ischemic history, hemodynamic status, disease progression, and other patient-specific factors.
Clinical Reasoning Quiz
1. A 47-year-old man has recurrent migraine-like headaches. MRI demonstrates multiple flow voids around the Sylvian fissure, and MRA demonstrates severe proximal M1 stenosis with reduced distal MCA branches. What is the most appropriate interpretation?
① Brain aneurysm
② AVM
③ Moyamoya-pattern vasculopathy
④ Venous sinus thrombosis
⑤ Multiple sclerosis
Correct Answer: ③. Explanation: The combination of proximal MCA stenosis, distal branch reduction, and abnormal collateral vessels strongly suggests moyamoya-pattern vasculopathy.
2. Which finding is least characteristic of moyamoya?
① Puff of smoke sign
② Ivy sign
③ Brush sign
④ Basal ganglia flow voids
⑤ Solitary tumor-like enhancement
Correct Answer: ⑤. Explanation: The other findings can occur in association with moyamoya vascular changes, whereas solitary tumor-like enhancement is not a characteristic imaging feature.
3. Which factor is particularly important when considering treatment?
① Headache frequency alone
② Serum cholesterol alone
③ Stenosis together with cerebral perfusion and cerebrovascular reserve
④ Anticoagulation in every patient
⑤ No further imaging
Correct Answer: ③. Explanation: The functional consequence of vascular stenosis is central to treatment planning.
Future Precision Neurovascular Imaging
The future of moyamoya imaging is unlikely to depend on a single superior modality.
Instead, the field is moving toward integration of:
Vascular morphology + vessel wall + collateral architecture + perfusion + CVR + parenchymal injury + longitudinal change.
Emerging technologies include:
- High-resolution vessel-wall MRI
- Quantitative perfusion MRI
- Advanced ASL
- Radiomics
- Deep learning
- Multimodal foundation models
- Longitudinal AI monitoring
- Automated vascular segmentation
- Digital neurovascular phenotyping
AI may eventually help transform serial imaging into a dynamic representation of disease progression.
But the critical principle remains unchanged:
An algorithm must understand the clinical question before its output becomes clinically useful.
Conclusion
The most important lesson from this case is not that migraine-like headache can occur in moyamoya.
It is that clinical phenotype and vascular biology do not always tell the same story.
The 47-year-old man presented with recurrent headache, photophobia, phonophobia, and nausea—symptoms that naturally suggest migraine. Yet MRI revealed abnormal vascular structures around the left Sylvian fissure, while TOF-MRA demonstrated severe proximal left M1 stenosis and reduced distal MCA visualization.
The diagnostic turning point was recognizing the combination:
stenosis + collateralization + altered distal vascular pattern.
That combination should trigger consideration of moyamoya vasculopathy.
The next step is not simply to ask how narrow the artery is.
The more important questions are:
How has the brain compensated?
Is cerebral perfusion preserved?
Is cerebrovascular reserve impaired?
Has the brain already sustained ischemic or hemorrhagic injury?
Could the vascular phenotype represent MMD or MMS?
Would revascularization be appropriate?
And, increasingly:
Can AI help identify these patterns earlier without introducing new clinical errors?
Modern moyamoya imaging is therefore no longer a single-modality exercise. It is an integrated assessment of vascular anatomy, collateral circulation, cerebral hemodynamics, brain injury, and longitudinal change.
That is the level at which the radiologist can move beyond simply identifying stenosis and begin to understand the disease process itself.
Key Takeaways
- Migraine-like headache does not exclude moyamoya angiopathy.
- Severe M1 stenosis should be interpreted together with the collateral vascular pattern.
- Sylvian fissure flow voids can provide an important imaging clue.
- TOF-MRA is useful for noninvasive assessment.
- DSA remains central for detailed vascular characterization and surgical planning.
- Perfusion and cerebrovascular reserve provide information that luminal imaging cannot provide.
- MMD and MMS should not be treated as interchangeable terms.
- Revascularization is an important treatment strategy in appropriately selected patients.
- AI may improve detection and longitudinal analysis but remains a decision-support technology.
- The ultimate imaging goal is to understand vascular anatomy + collateralization + perfusion + tissue injury as one clinical system.
Medical Disclaimer
This article is intended for medical education and does not substitute for professional diagnosis or treatment. Individual symptoms, imaging findings, and treatment decisions require evaluation by an appropriately qualified physician or neurovascular multidisciplinary team.
References
- R. M. Scott and E. R. Smith, “Moyamoya disease and moyamoya syndrome,” New England Journal of Medicine, vol. 360, no. 12, pp. 1226–1237, 2009. doi: 10.1056/NEJMra0804622.
- J. A. Berry, V. Cortez, H. Toor, H. Saini, and J. Siddiqi, “Moyamoya: An update and review,” Cureus, vol. 12, no. 10, e10994, 2020. doi: 10.7759/cureus.10994.
- J. Li, M. Jin, X. Sun, et al., “Imaging of Moyamoya Disease and Moyamoya Syndrome: Current Status,” Journal of Computer Assisted Tomography, vol. 43, no. 2, pp. 257–263, 2019. doi: 10.1097/RCT.0000000000000834.
- M. Velo, G. Grasso, M. Fujimura, et al., “Moyamoya vasculopathy: Cause, clinical manifestations, neuroradiologic features, and surgical management,” World Neurosurgery, vol. 159, pp. 409–425, 2022. doi: 10.1016/j.wneu.2021.11.026.
- M. Ihara, Y. Yamamoto, Y. Hattori, et al., “Moyamoya disease: diagnosis and interventions,” The Lancet Neurology, vol. 21, no. 8, pp. 747–758, 2022. doi: 10.1016/S1474-4422(22)00165-X.
- N. R. Gonzalez, S. Amin-Hanjani, O. Y. Bang, et al., “Adult Moyamoya Disease and Syndrome: Current Perspectives and Future Directions: A Scientific Statement From the American Heart Association/American Stroke Association,” Stroke, vol. 54, no. 10, pp. e465–e479, 2023. doi: 10.1161/STR.0000000000000443.
- M. Fujimura, T. Tominaga, S. Kuroda, et al., “2021 Japanese Guidelines for the Management of Moyamoya Disease,” Neurologia Medico-Chirurgica, vol. 62, no. 4, pp. 165–170, 2022. doi: 10.2176/jns-nmc.2021-0382.
- S. Kuroda, M. Fujimura, J. Takahashi, et al., “Diagnostic Criteria for Moyamoya Disease – 2021 Revised Version,” Neurologia Medico-Chirurgica, 2022.
- N. Horie, M. Morikawa, A. Nozaki, et al., “‘Brush sign’ on susceptibility-weighted MR imaging indicates the severity of moyamoya disease,” AJNR American Journal of Neuroradiology, vol. 32, no. 9, pp. 1697–1702, 2011. doi: 10.3174/ajnr.A2589.
- H. K. Yoon, H. J. Shin, and Y. W. Chang, “‘Ivy sign’ in childhood moyamoya disease: Depiction on FLAIR and contrast-enhanced T1-weighted MR images,” Radiology, vol. 223, no. 2, pp. 384–389, 2002. doi: 10.1148/radiol.2232010839.
- C. Novillo-Solis, M. Salvador-Orbea, A. Morales-Acosta, and J. E. Leon-Rojas, “Imaging-Based Diagnostic Approaches in Moyamoya Disease: A Scoping Review,” Journal of Clinical Medicine, vol. 15, no. 6, 2410, 2026. doi: 10.3390/jcm15062410.
- M. Shahabi, N. Zareshahi, I. Kiani, et al., “High-resolution vessel wall MRI in Moyamoya disease: a systematic review and meta-analysis of diagnostic and prognostic applications,” Magnetic Resonance Materials in Physics, Biology and Medicine, vol. 67, no. 2, pp. 299–319, 2025. doi: 10.1007/s00234-024-03515-8.
- C.-C. Chiang, A. H. Shahid, A. M. Harriott, et al., “Evaluation and treatment of headache associated with moyamoya disease: a narrative review,” Cephalalgia, vol. 42, no. 6, pp. 542–552, 2022. doi: 10.1177/03331024211056250.
- N. Rifino, A. H. Aamodt, M. Wiedmann, et al., “The Spectrum of Headaches in Moyamoya Angiopathy: From Mechanisms to Management Strategies—A Consensus Review From the NEUROVASC Working Group,” European Journal of Neurology, vol. 32, no. 10, e70316, 2025. doi: 10.1111/ene.70316.
- L. S. Santana, M. Leite, M. H. Yoshikawa, et al., “Evaluation of deep learning algorithms in detecting moyamoya disease: a systematic review and single-arm meta-analysis,” Neurosurgical Review, vol. 47, no. 1, 300, 2024. doi: 10.1007/s10143-024-02537-3.
- H. Huang, X. Zheng, Y. Feng, and S. Shao, “Research progress of artificial intelligence in moyamoya disease,” 2025.
Comments
Post a Comment